QT Imaging enters feasibility study agreement with Canon Medical Systems for ultrasound breast scanner evaluation

QT IMAGING HOLDINGS, INC.

Canon will evaluate QT Scanner for business, technical, clinical value including quality validation, manufacturing, regulatory, market validation.
Term runs from March 28, 2024 through end of December 2024 or until superseded by a definitive collaboration agreement.
QTI grants Canon first priority in negotiations for collaborations (joint development, contract manufacturing, marketing) regarding ultrasound breast scanners.
Each party bears own expenses; QTI provides existing technical materials with no significant additional cost.
Canon has no right to reverse engineer; QTI retains all IP; liability limited to $1,000 (except for personal injury/property damage).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

QT IMAGING HOLDINGS, INC. entered into Feasibility Study Agreement with Canon Medical Systems Corporation valued at Standard terms with no upfront consideration; each party bears own expenses except as otherwise agre (effective 2024-03-28).

Action: entry
Agreement: collaboration
Counterparty: Canon Medical Systems Corporation
Value: Standard terms with no upfront consideration; each party bears own expenses except as otherwise agre
Effective: 2024-03-28

Exact text from the filing

On March 28, 2024, QT Imaging Holdings, Inc., a Delaware corporation (the “ Company ”), entered into a Feasibility Study Agreement (the “ Feasibility Study Agreement ”) with Canon Medical Systems Corporation, a company organized and existing under the laws of Japan (“ Canon ”).

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

QT IMAGING HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-082707

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.